These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 12478242)

  • 1. Does chemoprevention of Barrett's esophagus using acid suppression and/or COX-2 inhibition prevent neoplastic progression?
    Fennerty MB
    Rev Gastroenterol Disord; 2002; 2 Suppl 2():S30-7. PubMed ID: 12478242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The clinical strategy for the Barrett's esophagus].
    Kitabatake S; Niwa Y; Goto H
    Nihon Rinsho; 2005 Aug; 63(8):1434-7. PubMed ID: 16101235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Barrett's-related esophageal adenocarcinoma: is chemoprevention a potential option?
    Fennerty MB; Triadafilopoulos G
    Am J Gastroenterol; 2001 Aug; 96(8):2302-5. PubMed ID: 11513166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Review article: management of oesophageal adenocarcinoma -- control of acid, bile and inflammation in intervention strategies for Barrett's oesophagus.
    Jankowski JA; Anderson M
    Aliment Pharmacol Ther; 2004 Oct; 20 Suppl 5():71-80; discussion 95-6. PubMed ID: 15456468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Barrett's esophageal adenocarcinoma].
    Nakamura T
    Gan To Kagaku Ryoho; 2004 Mar; 31(3):322-6. PubMed ID: 15045933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gastrin-induced cyclooxygenase-2 expression in Barrett's carcinogenesis.
    Abdalla SI; Lao-Sirieix P; Novelli MR; Lovat LB; Sanderson IR; Fitzgerald RC
    Clin Cancer Res; 2004 Jul; 10(14):4784-92. PubMed ID: 15269153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Medical treatment of Barrett's esophagus].
    Kinoshita Y; Yuki T
    Nihon Rinsho; 2005 Aug; 63(8):1449-53. PubMed ID: 16101238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence.
    Morris CD; Armstrong GR; Bigley G; Green H; Attwood SE
    Am J Gastroenterol; 2001 Apr; 96(4):990-6. PubMed ID: 11316217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medical treatment of Barrett's esophagus: can it prevent cancer?
    Sampliner RE
    Surg Oncol Clin N Am; 2009 Jul; 18(3):503-8. PubMed ID: 19500739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of COX-2 expression with corresponding active and chronic inflammatory reactions in Barrett's metaplasia and progression to cancer.
    Ling FC; Baldus SE; Khochfar J; Xi H; Neiss S; Brabender J; Metzger R; Drebber U; Dienes HP; Bollschweiler E; Hoelscher AH; Schneider PM
    Histopathology; 2007 Jan; 50(2):203-9. PubMed ID: 17222248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemoprevention of adenocarcinoma associated with Barrett's esophagus: potential options.
    Neumann H; Mönkemüller K; Vieth M; Malfertheiner P
    Dig Dis; 2009; 27(1):18-23. PubMed ID: 19439956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Barrett's adenocarcinoma].
    Mafune K
    Nihon Rinsho; 2005 Aug; 63(8):1463-9. PubMed ID: 16101241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Chemoprevention in adenocarcinoma of the esophagus].
    Lanas A; Alcedo González J
    Acta Gastroenterol Latinoam; 2007 Mar; 37(1):37-48. PubMed ID: 17486744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclooxygenase-2 inhibitor therapy for the prevention of esophageal adenocarcinoma in Barrett's esophagus.
    Gupta RA; DuBois RN
    J Natl Cancer Inst; 2002 Mar; 94(6):406-7. PubMed ID: 11904306
    [No Abstract]   [Full Text] [Related]  

  • 15. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas.
    Wilson KT; Fu S; Ramanujam KS; Meltzer SJ
    Cancer Res; 1998 Jul; 58(14):2929-34. PubMed ID: 9679948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of proton pump inhibitors on markers of risk for high-grade dysplasia and oesophageal cancer in Barrett's oesophagus.
    Hillman LC; Chiragakis L; Shadbolt B; Kaye GL; Clarke AC
    Aliment Pharmacol Ther; 2008 Feb; 27(4):321-6. PubMed ID: 18047565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What's new in columnar lined esophagus (Barrett's metaplasia)?
    Tadiparthi R; Bansal A; Sharma P
    Curr Opin Gastroenterol; 2008 Jul; 24(4):516-20. PubMed ID: 18622169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclooxygenase-2 in Barrett's esophagus, Barrett's adenocarcinomas, and esophageal SCC: ready for clinical trials.
    Lord RV; Danenberg KD; Danenberg PV
    Am J Gastroenterol; 1999 Aug; 94(8):2313-5. PubMed ID: 10445576
    [No Abstract]   [Full Text] [Related]  

  • 19. Antiproliferative and apoptotic effects of rofecoxib on esophageal cancer in vitro(1).
    Vona-Davis L; Riggs DR; Jackson BJ; McFadden DW
    J Surg Res; 2004 Jun; 119(2):143-8. PubMed ID: 15145696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonsteroidal anti-inflammatory drugs and the esophageal inflammation-metaplasia-adenocarcinoma sequence.
    Anderson LA; Johnston BT; Watson RG; Murphy SJ; Ferguson HR; Comber H; McGuigan J; Reynolds JV; Murray LJ
    Cancer Res; 2006 May; 66(9):4975-82. PubMed ID: 16651456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.